

Module-1 Administrative Information and Product Information

1.5.1.1 Name of the medicinal Product

Amlodipine Besilate Tablets 5 mg

1.5.1.2 Qualitative and Quantitative Composition

1.5.1.2.1 Qualitative declaration

Amlodipine Besilate BP

1.5.1.2.2 Quantitative declaration

Sr. No	Ingredients	Specification	Standard Quantity (mg/tablet)	Reason for Inclusion
01	Amlodipine Besilate Eq. to Amlodipine	BP	6.930 Eq. To 5.000	Calcium Channel Antagonists
02	Microcrystalline Cellulose (PH 102)	BP	83.07	Diluent
03	Sodium Starch Glycolate (TYPE-A)	BP	6.000	Disintegrant
04	Calcium Hydrogen Phosphate (Anhydrous)	BP	42.00	Diluent
05	Magnesium Stearate	BP	2.000	Lubricant

1.5.1.3 Pharmaceutical Form

Oral Tablet

White to off-white coloured, round shaped, biconvex, uncoated tablets, breakline on one side and plain on other side.

1.5.1.4 Clinical Particulars

1.5.1.4.1 Therapeutic Indications

Amlodipine Besilate Tablets is indicated for hypertension, chronic stable angina and vasospastic angina (Prinzmetal's or variant angina). Amlodipine Besilate Tablets may be used as monotherapy or in combination with other antihypertensive or antianginal drugs.

1.5.1.4.2 Posology and Method of Administration



Module-1 Administrative Information and Product Information

Hypertension: Initial dose of 5 mg once daily, with a maximum dose of 10 mg once daily, Small, fragile or elderly individuals or patients with hepatic insufficiency may be started on 2.5 mg once daily and this dose may be used when adding amlodipine to other anti-hypertensive therapy.

Chronic stable or vasospastic angina: 5 - 10 mg with a lower dose (2.5 mg) in the elderly and in patients with hepatic insufficiency.

Children: The effective antihypertensive oral dose in paediatric patients (6-17 years) is 2.5 mg to 5 mg once daily. Doses in excess of 5 mg daily have not been studied in paediatric patients.

1.5.1.4.3 Contraindications

Hypersensitivity to amlodipine or any component of the formulation.

1.5.1.4.4 Special Warnings and Special Precautions for Use

Increased angina and/or MI has occurred with initiation or dosage titration of calcium channel blockers. Use caution in severe aortic stenosis. Use caution in patients with severe hepatic impairment. Dosage titration should occur after 7 - 14 days on a given dose.

Pregnancy Implications: Embryotoxic effects have been demonstrated in small animals. No well-controlled studies have been conducted in pregnant women. Use in pregnancy only when clearly needed and when the benefits outweigh the potential hazard to the fetus,

Lactation : Excretion in breast milk unknown/not recommended.

1.5.1.4.5 Interaction with other medicinal products and other forms of interaction

In clinical trials, amlodipine has been safely administered with thiazide diuretics, beta-Blockers, angiotensin converting enzyme inhibitors, long acting nitrates, sublingual nitroglycerin, digoxin warfarin, non steroidal anti-inflammatory drugs, antibiotics and oral hypoglycemic drugs.

1.5.1.4.6 Fertility, Pregnancy and Lactation

Pregnancy Implications: Embryotoxic effects have been demonstrated in small animals. No well-controlled studies have been conducted in pregnant women. Use in pregnancy only when clearly needed and when the benefits outweigh the potential hazard to the fetus,

Lactation : Excretion in breast milk unknown/not recommended.



Module-1 Administrative Information and Product Information

1.5.1.4.7 Effects on ability To Drive and use Machines

None.

1.5.1.4.8 Undesirable Effects

Amlodipine is well tolerated. Side effects include headache, oedema, fatigue, somnolence, nausea, abdominal pain, flushing, palpitations and dizziness.

Less commonly observed are pruritus, rash, dyspnoea, asthenia, muscle cramps and dyspepsia. Rarely, myocardial infarction and chest pain have been reported.

1.5.1.4.9 Overdose

Primary cardiac symptoms of calcium channel blocker overdose include hypotension and bradycardia. Noncardiac symptoms include confusion, stupor, nausea, vomiting, metabolic acidosis, and hyperglycemia. Treat other signs and symptoms symptomatically.

1.5.1.5 Pharmacological Properties

1.5.1.5.1 Pharmacodynamics Properties

Inhibits calcium ion from entering the "slow channels" or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina.

1.5.1.5.2 Pharmacokinetic Properties

After oral administration of therapeutic doses of amlodipine, absorption produces peak plasma concentrations between 6 and 12 hours. Absolute bioavailability has been estimated to be between 64 and 90%. The bioavailability of amlodipine is not altered by the presence of food. Amlodipine is extensively (about 90%) converted to inactive metabolites via hepatic metabolism with 10% of the parent compound and 60% of the metabolites excreted in the urine. Elimination from the plasma is biphasic with a terminal elimination half-life of about 30-50 hours. SteadyState plasma levels of amlodipine are reached after 7 to 8 days of consecutive daily dosing.

The pharmacokinetics of amlodipine are not significantly influenced by renal impairment. Patients with renal failure may therefore receive the usual initial dose.

Module-1 Administrative Information and Product Information

Elderly: patients and patients with hepatic insufficiency have decreased clearance of amlodipine with a resulting: increase in AUC of approximately 40-60%, and a lower initial dose may be required. A similar increase in AUC was observed in patients with moderate to severe heart failure.

Paediatric Patients: Sixty-two hypertensive patients aged 6 to 17 years received doses of amlodipine between 1.25 mg and 20 mg. Weight-adjusted clearance and volume of distribution were similar to values in adults.

1.5.1.5.3 Preclinical Safety Data

No other relevant preclinical data is available.

1.5.1.6 Pharmaceutical Particulars

1.5.1.6.1 List of Excipients

Microcrystalline Cellulose (PH 102) BP

Sodium Starch Glycolate (TYPE-A) BP

Calcium Hydrogen Phosphate (Anhydrous) BP

Magnesium Stearate BP

1.5.1.6.2 Incompatibilities

Not applicable.

1.5.1.6.3 Shelf Life

36 months

1.5.1.6.4 Special Precautions for Storage

Store below 30°C. Protect from light.

1.5.1.6.5 Nature and Contents of Container

Such 10 tablets are packed in Strip pack. Such 3 Strip packs are packed in a printed baby carton & Such 10 baby carton are packed in a printed mother carton with packing insert.



Module-1 Administrative Information and Product Information

1.5.1.6.6 Special precaution for disposal and other handling

Any unused product or waste material should be disposed of in accordance with local requirements.

Keep the medicine out of reach of children

1.5.1.7 Marketing Authorization Holder And Manufacturing Site Addresses

1.5.1.7.1 Name and Address of Marketing Authorization Holder

SENES PHARMA CO. LTD.

Michel Camp Road, Comm 21/22,

juno, Tema, Ghana

Telephone no.: 022 302574

Fax: 022 307407

Email: senespharm@yahoo.com

1.5.1.7.2 Name and Address of manufacturing site(s)

Lincoln Pharmaceuticals Limited

Trimul Estate, Khatraj, Taluka: Kalol,

District: Gandhinagar Gujarat, India.

Telephone no.: +91-079-41078096

Fax: +91-079-41078062

Email: hiren@lincolnpharma.com

Website: www.lincolnpharma.com

1.5.1.8 Date Of Publication Or Revision

17.08.2020